Singh, Abhay
Herr, Megan M.
Griffiths, Elizabeth A.
Przespolewski, Amanda
Faber, Mark G.
Mrad, Chebli
Wang, Eunice S.
Hahn, Theresa
Thota, Swapna
Article History
Received: 4 August 2021
Accepted: 17 November 2021
First Online: 2 December 2021
Competing interests
: E.G.—Serves as Scientific advisor for AbbVie, Inc., Alexion Pharmaceuticals, Inc., Boston Biomedical, Celgene Corporation/Bristol-Myers Squibb, Partner Therapeutics, and Persimmune. Receives honoraria from AbbVie, Inc., Boston Biomedical, and Novartis Pharmaceuticals Corporation; receives grant/research support (to Roswell Park Cancer Institute) from Astex Pharmaceuticals, Celgene Corporation/Bristol-Meyers Squibb and Genentech, Inc. E.W.—Serves on advisory board for Abbvie, Astellas, BMS/Celgene, Genentech, Jazz, Kite Pharmaceuticals, Macrogenics, Pfizer, PTC Therapeutics, Stemline, Takeda, BMS (Celgene). Speaker role: Stemline, Pfizer, Dava Oncology. Data monitoring committees: Abbvie, Rafael Pharmaceuticals. Other authors disclose no conflicts of interest.